Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:AKRO NASDAQ:MIRM NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$15.98+0.0%$17.13$13.50▼$25.67$3.83B0.543.15 million shs208,687 shsAKROAkero Therapeutics$47.52-0.7%$47.86$21.34▼$58.40$3.81B-0.241.37 million shs162,439 shsMIRMMirum Pharmaceuticals$74.05+0.6%$65.26$36.88▼$78.10$3.73B0.92532,153 shs69,142 shsSPRYARS Pharmaceuticals$9.68-2.6%$14.18$9.38▼$18.90$955.35M0.881.75 million shs267,825 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-0.31%+1.85%-10.22%-9.20%-20.22%AKROAkero Therapeutics+3.08%+12.30%-2.82%-13.08%+68.63%MIRMMirum Pharmaceuticals-0.42%-0.23%+2.94%+46.86%+89.11%SPRYARS Pharmaceuticals+1.53%+5.63%-26.37%-42.41%-29.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$15.98+0.0%$17.13$13.50▼$25.67$3.83B0.543.15 million shs208,687 shsAKROAkero Therapeutics$47.52-0.7%$47.86$21.34▼$58.40$3.81B-0.241.37 million shs162,439 shsMIRMMirum Pharmaceuticals$74.05+0.6%$65.26$36.88▼$78.10$3.73B0.92532,153 shs69,142 shsSPRYARS Pharmaceuticals$9.68-2.6%$14.18$9.38▼$18.90$955.35M0.881.75 million shs267,825 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-0.31%+1.85%-10.22%-9.20%-20.22%AKROAkero Therapeutics+3.08%+12.30%-2.82%-13.08%+68.63%MIRMMirum Pharmaceuticals-0.42%-0.23%+2.94%+46.86%+89.11%SPRYARS Pharmaceuticals+1.53%+5.63%-26.37%-42.41%-29.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6773.11% UpsideAKROAkero Therapeutics 3.00Buy$81.1470.76% UpsideMIRMMirum Pharmaceuticals 3.09Buy$76.503.31% UpsideSPRYARS Pharmaceuticals 3.14Buy$32.50235.81% UpsideCurrent Analyst Ratings BreakdownLatest SPRY, ADMA, MIRM, and AKRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/24/2025MIRMMirum PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy9/24/2025MIRMMirum PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$95.009/12/2025MIRMMirum PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $77.009/4/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.009/4/2025SPRYARS PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.008/11/2025MIRMMirum PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$89.008/8/2025MIRMMirum PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$77.00 ➝ $89.008/7/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy8/7/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetMarket Outperform$79.00 ➝ $81.008/7/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$77.00 ➝ $82.008/7/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$73.00 ➝ $80.00(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M8.94$0.54 per share29.62$1.48 per share10.80AKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AMIRMMirum Pharmaceuticals$336.89M11.04N/AN/A$4.70 per share15.75SPRYARS Pharmaceuticals$112.34M8.51$0.01 per share1,156.08$2.64 per share3.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8618.6723.16N/A44.06%41.01%28.47%11/6/2025 (Estimated)AKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%11/14/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.49N/AN/AN/A-42.74%-21.85%-15.88%11/12/2025 (Estimated)Latest SPRY, ADMA, MIRM, and AKRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SPRYARS Pharmaceuticals-$0.41-$0.46-$0.05-$0.46$12.92 million$15.72 million8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 million8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.215.332.78AKROAkero Therapeutics0.0212.6612.66MIRMMirum Pharmaceuticals1.213.132.97SPRYARS Pharmaceuticals0.376.175.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AKROAkero TherapeuticsN/AMIRMMirum PharmaceuticalsN/ASPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%AKROAkero Therapeutics7.07%MIRMMirum Pharmaceuticals22.87%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.63 million229.80 millionOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableMIRMMirum Pharmaceuticals14050.24 million38.75 millionOptionableSPRYARS Pharmaceuticals9098.83 million65.72 millionOptionableSPRY, ADMA, MIRM, and AKRO HeadlinesRecent News About These CompaniesARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Rating of "Buy" from AnalystsSeptember 24 at 2:48 AM | marketbeat.comARS Pharmaceuticals: A Significant Upside Is Expected From neffySeptember 23 at 3:01 AM | seekingalpha.comHarbour Capital Advisors LLC Purchases 29,300 Shares of ARS Pharmaceuticals, Inc. $SPRYSeptember 21 at 8:51 AM | marketbeat.comARS Pharmaceuticals announces neffy approved in JapanSeptember 19, 2025 | msn.comARS Pharmaceuticals stock rises after Japan approves needle-free epinephrine spraySeptember 19, 2025 | investing.comneffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)September 19, 2025 | finance.yahoo.comARS Pharmaceuticals and Alfresa Holdings Receive Japanese Approval for neffy® Epinephrine Nasal Spray to Treat AnaphylaxisSeptember 19, 2025 | quiverquant.comQARS Pharmaceuticals, Inc. (SPRY): A Bull Case TheorySeptember 18, 2025 | finance.yahoo.comARS Pharmaceuticals, Inc. (SPRY): A Bull Case TheorySeptember 18, 2025 | msn.comARS Pharmaceuticals, Inc. (SPRY): A Bull Case Theory September 17, 2025 | insidermonkey.comADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board ChairSeptember 17, 2025 | globenewswire.comARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week Low - What's Next?September 14, 2025 | marketbeat.comWoodline Partners LP Sells 518,961 Shares of ARS Pharmaceuticals, Inc. $SPRYSeptember 14, 2025 | marketbeat.comOctagon Capital Advisors LP Buys Shares of 625,000 ARS Pharmaceuticals, Inc. $SPRYSeptember 11, 2025 | marketbeat.comARS Pharmaceuticals announces real-world evidence on neffy effectivenessSeptember 9, 2025 | finance.yahoo.comAlliancebernstein L.P. Has $49.35 Million Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 9, 2025 | marketbeat.comWhat is Roth Capital's Estimate for SPRY Q3 Earnings?September 9, 2025 | marketbeat.comReal-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing AnaphylaxisSeptember 8, 2025 | globenewswire.comAlyeska Investment Group L.P. Cuts Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 8, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week Low - Should You Sell?September 8, 2025 | marketbeat.comTrexquant Investment LP Buys 44,206 Shares of ARS Pharmaceuticals, Inc. $SPRYSeptember 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Vertical Aerospace: An Analyst's Roadmap to a Potential Re-RatingBy Jeffrey Neal Johnson | August 27, 2025The Uber Eats Partnership Fueling Serve Robotics' GrowthBy Jeffrey Neal Johnson | August 28, 2025The Quiet Before the Catalyst: Vertical Aerospace's Next MoveBy Jeffrey Neal Johnson | September 9, 2025SPRY, ADMA, MIRM, and AKRO Company DescriptionsADMA Biologics NASDAQ:ADMA$15.98 +0.00 (+0.01%) As of 11:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Akero Therapeutics NASDAQ:AKRO$47.52 -0.32 (-0.67%) As of 11:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Mirum Pharmaceuticals NASDAQ:MIRM$74.05 +0.43 (+0.58%) As of 11:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.ARS Pharmaceuticals NASDAQ:SPRY$9.68 -0.26 (-2.64%) As of 11:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm’s RSI Just Hit Its High of the Year—Why That’s Bullish 2 Ways to Trade Amazon Ahead of October’s Prime Day AutoZone Pulls Into a Buy-the-Dip Opportunity Rocket Lab’s Bullish Case Remains Intact Despite Recent Offering Broadcom Price Targets Just Reached Above $400 for the First Time These 3 Mega-Cap Giants Just Increased Dividends by 7% or More 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
